SCHEMBL2830965

SCHEMBL2830965

CNc1scnc1C(=O)Nc1cccc(C)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.55
MEN1 O00255 6/20 0.55
KMT2A Q03164 6/20 0.55
ALDH1A1 P00352 4/20 0.55
MAPT P10636 3/20 0.55
KDM4E B2RXH2 2/20 0.55
RXFP1 Q9HBX9 2/20 0.52
LMNA P02545 2/20 0.51
FLT1 P17948 1/20 0.51
KDR P35968 1/20 0.51
TP53 P04637 5/20 0.50
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
FLT3 P36888 1/20 0.50
MAP4K1 Q92918 1/20 0.50
NAMPT P43490 1/20 0.49
KCNK3 O14649 2/20 0.49
KCNK9 Q9NPC2 2/20 0.49
HSD17B10 Q99714 3/20 0.49
KCNH2 Q12809 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2826489 0.87 KMT2A (0.53) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
SCHEMBL2829990 0.86 MEN1 (0.52) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
SCHEMBL2827185 0.86 SMN1; SMN2 (0.52) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
SCHEMBL2824725 0.85 KMT2A (0.51) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
SCHEMBL2829644 0.84 NAMPT (0.51) SMN1; SMN2ALDH1A1MAPTKDM4ELMNA
SCHEMBL2829315 0.83 LMNA (0.51) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
SCHEMBL2827214 0.83 SMN1; SMN2 (0.49) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
SCHEMBL2826632 0.83 NPC1 (0.54) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
SCHEMBL2827700 0.83 MEN1 (0.49) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
SCHEMBL2829382 0.82 KMT2A (0.48) SMN1; SMN2MEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1844044-B1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-07-21 EP claimed
US-7678815-B2 Thiazole-4-carboxyamide derivatives HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US claimed
EP-1844044-A1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2007-10-17 EP claimed
US-20060160857-A1 Thiazole-4-carboxyamide derivatives HOFFMANN-LA ROCHE INC. 2006-07-20 US claimed
WO-2006074884-A1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2006-07-20 WO claimed
EP-1844044-B1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-07-21 EP disclosed
US-7678815-B2 Thiazole-4-carboxyamide derivatives HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1844044-A1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2007-10-17 EP disclosed
US-20060160857-A1 Thiazole-4-carboxyamide derivatives HOFFMANN-LA ROCHE INC. 2006-07-20 US disclosed
WO-2006074884-A1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160857-A1 Thiazole-4-carboxyamide derivatives GRM1, GRM2, GRIA4 SMN1; SMN2 3071/4885MEN1 2558/4885KMT2A 1012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.